MicuRx(SH:688373) Ge Long Hui A P P·2026-02-26 08:24Core Viewpoint - Amgen Pharmaceuticals (688373.SH) reported a total operating revenue of 142 million yuan for the fiscal year 2025, reflecting a year-on-year growth of 8.83% [1] Financial Performance - The net profit attributable to the parent company was a loss of 242 million yuan, which is a decrease in loss by 199 million yuan year-on-year [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was a loss of 250 million yuan, representing a decrease in loss by 209 million yuan year-on-year [1] Product and Market Development - During the reporting period, the company had only one product, Kanti Zuoan tablets, in the commercialization stage [1] - The company is actively exploring a market development model that combines self-operated teams with commercial distribution, but due to being in a transitional phase, various collaborations have not yet fully launched, resulting in a slight year-on-year increase in main business revenue [1]